Evidence map›Paper›PMID 39000144›Full record

ArticleInternational journal of molecular sciences2024

Investigating the Effectiveness of Ceragenins against

Maciej Karasiński, Urszula Wnorowska, Tamara Daniluk, Piotr Deptuła, Milena Łuckiewicz, Paulina Paprocka, Bonita Durnaś, Karol Skłodowski, Beata Sawczuk, Paul B Savage and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maciej KarasińskiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.ORCID 0009-0001-3961-0717
Urszula WnorowskaDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.
Tamara DanilukDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.
Piotr DeptułaIndependent Laboratory of Nanomedicine, Medical University of Białystok, 15-222 Białystok, Poland.
Milena ŁuckiewiczIndependent Laboratory of Nanomedicine, Medical University of Białystok, 15-222 Białystok, Poland.
Paulina PaprockaDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, 25-317 Kielce, Poland.ORCID 0000-0002-3626-8151
Bonita DurnaśDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, 25-317 Kielce, Poland.
Karol SkłodowskiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.
Beata SawczukDepartment of Prosthodontics, Medical University of Bialystok, Sklodowskiej 24a, 15-276 Bialystok, Poland.ORCID 0000-0002-4131-8627
Paul B SavageDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA.
Ewelina PiktelIndependent Laboratory of Nanomedicine, Medical University of Białystok, 15-222 Białystok, Poland.
Robert BuckiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.ORCID 0000-0001-7664-9226

Funding

Medical University of Białystok B.sub.24.414
6 · The paper itself

Abstract

A growing body of experimental data indicates that ceragenins (CSAs), which mimic the physicochemical properties of the host's cationic antimicrobial peptide, hold promise for the development of a new group of broad-spectrum antimicrobials. Here, using a set of in vivo experiments, we assessed the potential of ceragenins in the eradication of an important etiological agent of nosocomial infections,

Indexed as

Acinetobacter baumanniiBacterial AdhesionBiofilmsSteroidsA549 CellsAcinetobacter InfectionsAnti-Bacterial AgentsHumansMicrobial Sensitivity TestsAnti-Bacterial Agentsceragenin CSA-13cerageninsSteroidsAcinetobacter baumanniianti-adhesive strategiesantimicrobialatomic force microscopybiofilmceragenins

Identifiers

PMID39000144
PMCPMC11241064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.